SLIDESHOW: 10 Oversold ETFs
By ETF Channel Staff, updated Sun, October 1, 10:26 PM
(1) Invesco Biotechnology & Genome Getting Very Oversold triggered: 09/29/2023

Fund Name: |
Invesco Biotechnology & Genome ETF |
Issuer: |
Invesco |
Total Net Assets: |
$224,825,000 |
Inception: |
06/23/2005 |
Related Index: |
DZOTR |
ETF Category: |
Health |
Expense Ratio: |
0.57% |
|
Net Asset Value: |
$57.50 |
Recent NAV Premium: |
0.00% |
NAV Symbol: |
PBE.NV |
Number of Holdings: |
31 |
Annualized Yield: |
0.02% |
Annualized Distribution: |
0.011 |
PBE Dividend History » |
|
Read full article in a new window: Invesco Biotechnology & Genome Getting Very Oversold
Open the ETF Channel PBE Page (in a new window) »

 Buy (3.24 out of 4)
57th percentile
 |
 |
Copyright © 2010 - 2023, All Rights Reserved
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use
and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.